PharmaGraphX

Log in Get Started

Erenumab

Aimovig

Monoclonal antibody

Standard

Half-life

28 days

Protein Binding

N/A

Metabolized By

N/A

External

Drugs.com

Mechanism of action

Monoclonal antibody that blocks CGRP receptor, preventing migraine pathophysiology

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Migraine
·Chronic Migraine
·Migraine Disorders
·Sleep Disorder
·Menstrual Migraine

Interactions

No curated interaction pairs are recorded for Erenumab. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Injection site reactions
Constipation
Muscle spasms

Pharmacokinetics

Half-life: 28 days
Protein binding: N/A

Pregnancy & lactation

Not recorded for Erenumab. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement